S. 515, H.R. 1260, Patent Reform Act of 2009, S. 525/1252, H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009, S. 729, H.R. 1427, Promoting Innovation and Access to Live-Savings Medicine Act of 2009
Reimbursement and regulation of pharmaceutical and biological products in P.L. 111-148 ( The Patient Protection and Affordable Care Act ) and P.L. 111-152 ( The Health Care and Education Reconciliation Act ).
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2009: House of Representatives, U.S. Senate, Congressional Budget Office (CBO)
Related Foreign Entities:
Boehringer Ingelheim GmbH (55216 Ingelheim, GER); contribution to lobbying: $0; ownership 100%
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Registration
Q1 Report
Registration
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...